Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Paul A. Heidenreich, Pamela B. Morris, Khurram Nasir, Erin D. Michos, Vera A. Bittner, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)2572-2574
Number of pages3
JournalCirculation
Volume135
Issue number25
DOIs
StatePublished - Jun 20 2017
Externally publishedYes

Keywords

  • cardiovascular disease
  • cholesterol
  • lipids

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this